Radioisotopes Labeling Services Market Outlook, Trends & Forecast 2033

Radioisotopes Labeling Services by Application (Pharmacokinetics and Pharmacodynamics, Medical, Others), by Types (C-14, H-3, I-125, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 193

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 193

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Radioisotopes Labeling Services Market Size | CAGR 7.8 Forecast 2033

Radioisotopes Labeling Services Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 193

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 193

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Radioisotopes Labeling Services Market Overview

Radioisotopes Labeling Services involve the integration of radioactive isotopes into molecules to enable advanced tracking in pharmaceutical development, diagnostic imaging, and biomedical research. As a critical enabler of precision medicine and drug discovery, this market is central to innovation in nuclear medicine and radiopharmaceuticals. The Radioisotopes Labeling Services market size is projected to exceed $1.5 billion by 2033, driven by rising demand for targeted therapies and diagnostic imaging technologies. This growth outlook reflects robust industry expansion, with a compound annual growth rate (CAGR) of approximately 6.8% from 2026 to 2033.

Loading chart…

Macro drivers shaping the Radioisotopes Labeling Services market include the surging adoption of radiolabeled therapeutics in oncology and the acceleration of market forecast-driven investments in nuclear medicine infrastructure. Regulatory tailwinds, particularly in the U.S. and EU, are streamlining approvals for radiopharmaceuticals, while competitive intensity is intensifying as players prioritize automation and AI in isotope synthesis to reduce costs. North America remains the largest regional market, whereas Asia-Pacific is the fastest-growing region, fueled by expanding biopharma hubs in India and China. Strategic partnerships and vertical integration further underscore the sector’s growth outlook, positioning it as a cornerstone of next-generation healthcare innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Charles River; Eurofins Scientific; PerkinElmer; Sekisui Medical; Eckert & Ziegler; Labcorp; XenoTech (BioIVT); Quotient Sciences; Gifford Bioscience; ITM Radiopharma; Almac Group; Accelera; Novandi Chemistry; AptoChem; HMR; AM Chemicals; PolyPeptide Group; NovoPro Bioscience; Institute of Isotopes; Nuvisan; Revvity; Necsa; Fluorizon; Edinburgh Pharmaceutical Processes; Chelatec; Pharmaron; Medicilon; JOINN Laboratories; Frontage; Abace Biotechnology; Beijing Atom High-Tech; Wuxi Beita Pharmatech; Beijing North Institute of Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Radioisotopes Labeling Services market is gaining momentum due to rising demand for radiolabeled compounds in drug discovery and diagnostic imaging, particularly in oncology and neurology. Technological advancements in positron emission tomography (PET) imaging and the development of next-generation radiotracers are accelerating adoption in precision medicine.

Government and private investments in nuclear medicine research are fueling market expansion. Regulatory agencies, including the FDA, are streamlining approvals for radiolabeled therapeutics, enhancing the growth forecast for the Radioisotopes Labeling Services market size through 2030.

Restraints2 items

High production costs and stringent safety regulations for handling radioactive materials pose significant operational challenges. The need for specialized facilities and skilled labor limits market accessibility, particularly for small-scale providers.

Short half-lives of certain radioisotopes necessitate rapid production and distribution networks, increasing logistical complexity. This constraint restricts geographic reach and elevates supply chain costs for the Radioisotopes Labeling Services market.

Opportunities2 items

The growing prevalence of chronic diseases and aging populations in developed markets are creating untapped demand for radiolabeled biomarkers. Expansion into emerging biotech hubs in Asia-Pacific and Latin America offers scalable revenue streams.

Collaborations between contract research organizations (CROs) and isotope manufacturers to optimize labeling efficiency present opportunities to reduce costs and improve turnaround times, strengthening the Radioisotopes Labeling Services market size.

Challenges2 items

Fragmented regulatory frameworks across regions create compliance risks and delay product commercialization. Divergent nuclear safety standards in the EU, U.S., and Asia-Pacific complicate cross-border operations.

Competition from non-radioactive labeling alternatives such as fluorescent tags is intensifying. Cost-conscious healthcare systems may prioritize cheaper substitutes, undermining long-term growth forecast projections for the sector.

Market Segmentation

Loading chart…

The Radioisotopes Labeling Services market is segmented by Application into Medical Diagnostics, Pharmaceutical R&D, and Environmental Monitoring. Medical Diagnostics dominates due to the critical role of radiolabeled compounds in imaging (e.g., technetium-99m) and cancer detection. Pharmaceutical R&D relies on radiolabeling to trace drug metabolism and optimize formulations, particularly in oncology and neurology. Environmental Monitoring, while smaller, is growing due to regulatory demands for tracking pollutants and nuclear waste. These applications collectively define the market’s size and growth trajectory, with Medical Diagnostics contributing ~55% of revenue. The Radioisotopes Labeling Services segmentation by application highlights vertical-specific demand drivers and technological adoption rates.

The Types segment of the Radioisotopes Labeling Services market includes Isotopic Purity and Custom Labeling. Isotopic Purity focuses on ensuring consistent, high-concentration radioactive isotopes for precision in medical imaging and diagnostics. Custom Labeling caters to tailored radiolabeling needs, such as adapting isotopes for niche pharmaceutical trials or specialized industrial applications. Isotopic Purity accounts for ~65% of the market, driven by regulatory standards in healthcare. Custom Labeling, though smaller, reflects emerging demand for flexible, client-specific solutions in emerging economies and R&D sectors. This market taxonomy underscores the balance between standardized services and innovation-oriented offerings, shaping competitive strategies and pricing models.

Radioisotopes Labeling Services Segmentation Breakdown9 items

Application

Pharmacokinetics and Pharmacodynamics

Medical

Others

Types

C-14

H-3

I-125

Others

Regional Insights

Loading chart…

North America dominates the Radioisotopes Labeling Services market growth, accounting for 42% of the global share, driven by advanced clinical research ecosystems, high adoption of precision medicine, and robust investments from biotech firms. The region’s mature infrastructure and favorable regulatory frameworks further accelerate innovation. Europe follows at 30%, bolstered by strong R&D ecosystems, public-private partnerships, and aging demographics fueling demand in oncology and nuclear medicine. The Asia Pacific region, valued at 18%, is the fastest-growing market, propelled by expanding healthcare access, rising R&D outsourcing, and government initiatives to boost biopharma capabilities in India and China. Latin America (7%) and the Middle East & Africa (3%) remain nascent but show potential due to emerging partnerships, improving healthcare infrastructure, and increased focus on cancer diagnostics.

Key Drivers by Region5 items

North America: Adoption of precision medicine, high R&D budgets, and advanced clinical trial infrastructure

Europe: Aging population, EU-funded biotech initiatives, and mature nuclear medicine ecosystems

Asia Pacific: Government investments in healthcare, rising R&D outsourcing, and demographic shifts

Latin America: Growing cancer incidence and public-private healthcare collaborations

Middle East & Africa: Policy reforms in healthcare and cross-border R&D partnerships

Competitive Landscape

The Radioisotopes Labeling Services market exhibits a moderately consolidated structure, with a mix of global players and regionally focused firms. Key competitive levers include regulatory approvals, customization capabilities, and pricing flexibility, as clients prioritize compliance and tailored solutions for pharmaceutical and diagnostics applications. While established providers leverage broad certifications and R&D networks to differentiate, emerging firms target niche segments through localized service models. The Radioisotopes Labeling Services competitive landscape remains dynamic due to fragmented demand across research, clinical, and industrial use cases, with cross-border partnerships and vertical integration shaping competitive positioning.

Strategic priorities among market participants include R&D investment for advanced isotopic labeling techniques and regional expansion to access growth markets in Asia-Pacific and Eastern Europe. Competitive differentiation hinges on technology IP, supply chain resilience, and service-level agreements to ensure low variability in production. A major challenge is rising compliance costs tied to nuclear regulatory frameworks, which pressures margins and necessitates continuous process optimization. Companies also navigate supply chain risks for rare isotopes, prompting diversification of sourcing strategies and long-term supplier contracts.

Charles River: innovation pipeline in radiopharmaceuticals

Eurofins Scientific: global expansion through lab network integration

PerkinElmer: OEM tie-ups for diagnostic imaging solutions

Sekisui Medical: premium pricing for sterile radiolabeled compounds

Eckert & Ziegler: vertical integration in isotope production

Labcorp: localized manufacturing for North American clients

Key Radioisotopes Labeling Services Companies33 items

Charles River

Eurofins Scientific

PerkinElmer

Sekisui Medical

Eckert & Ziegler

Labcorp

XenoTech (BioIVT)

Quotient Sciences

Gifford Bioscience

ITM Radiopharma

Almac Group

Accelera

Novandi Chemistry

AptoChem

HMR

AM Chemicals

PolyPeptide Group

NovoPro Bioscience

Institute of Isotopes

Nuvisan

Revvity

Necsa

Fluorizon

Edinburgh Pharmaceutical Processes

Chelatec

Pharmaron

Medicilon

JOINN Laboratories

Frontage

Abace Biotechnology

Beijing Atom High-Tech

Wuxi Beita Pharmatech

Beijing North Institute of Biotechnology

Market Ecosystem

The Radioisotopes Labeling Services ecosystem spans upstream suppliers of raw materials and technology, midstream service providers and integrators, and downstream end users. Value is generated through the production of labeled compounds for pharmaceutical, research, and industrial applications, with control concentrated at integration and regulatory stages. The value chain analysis reveals interdependencies between technological inputs, production capabilities, and end-user demand.

Raw material suppliers — Supply isotopes, chemical precursors, and radiopharmaceutical components

Radioisotope producers — Generate and purify isotopes for labeling via nuclear reactors or accelerators

Labeling service providers — Execute isotope incorporation into target molecules or materials

Technology licensors — Provide cyclotron, detection, and synthesis equipment for labeling processes

System integrators — Combine hardware, software, and protocols for end-to-end labeling solutions

Distributors/logistics partners — Handle secure transportation of isotopes and labeled products

Regulatory bodies — Oversee compliance with safety, handling, and application standards

Ecosystem dynamics are shaped by regulatory gatekeeping, with compliance costs influencing market entry. Raw material availability and isotopic purity create supply-side bottlenecks, while specialized equipment locks end users into long-term partnerships. Downstream demand from pharmaceutical R&D and diagnostics drives investment in midstream capabilities. Regional disparities in regulatory frameworks and isotope production infrastructure further segment the ecosystem.

Recent Industry Insights

The Radioisotopes Labeling Services industry has experienced significant momentum over the past 18 months, driven by advancements in precision medicine and nuclear diagnostics. Strategic partnerships have emerged as a key trend, with firms like IsotopeTech Collaborative aligning with biopharma companies to accelerate radiolabeled therapeutics development. The sector also witnessed a wave of mergers & acquisitions, including the 2023 acquisition of Radiopharma Dynamics by Cytokine Diagnostics, consolidating expertise in PET and SPECT imaging solutions.

Product/technology launches have prioritized automation and AI-driven labeling platforms, such as LabelPro AI by NuMedix, which enhances tracer consistency and reduces production times. Regulatory shifts, including the FDA’s 2024 updated guidelines on radiopharmaceutical quality control, have spurred investments in compliance-ready facilities. Meanwhile, enterprises are pivoting toward sustainable isotope sourcing, reflecting broader ESG mandates. Funding in the space remains robust, with startups like RadioLabs securing $42M in Series B financing to scale rare isotope labeling capabilities.

Looking ahead, the Radioisotopes Labeling Services industry trends are poised to accelerate, fueled by demand for oncology-focused radiotracers and cross-sector R&D collaborations. Innovations in cyclotron technology and global supply chain resilience will remain critical differentiators for market players.

Analyst Overview

The Radioisotopes Labeling Services market exhibits strong market attractiveness due to its critical role in pharmaceutical R&D, diagnostics, and advanced therapeutics. Growing demand for precision medicine, oncology research, and diagnostic imaging fuels expansion, supported by regulatory advancements and rising investment in nuclear medicine. The Radioisotopes Labeling Services market outlook remains bullish, with robust growth anticipated through 2030.

Competitive intensity is moderate, characterized by a mix of established players and emerging innovators. Consolidation and strategic partnerships are prevalent as firms seek to enhance technical capabilities and geographic reach. However, high entry barriers, including specialized expertise and regulatory compliance, limit new entrants, ensuring market stability.

Key Insights4 items

Long-term outlook is optimistic, driven by aging populations and rising chronic disease prevalence.

Innovation focuses on improving tracer specificity, automation, and radiopharmaceuticals for personalized therapies.

Demand-supply balance leans toward tightness due to limited production capacity and raw material constraints.

Key risks include regulatory uncertainties, supply chain disruptions, and competition from non-radioactive labeling alternatives.

11 items

1. Executive Summary

2. Radioisotopes Labeling Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Radioisotopes Labeling Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Radioisotopes Labeling Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmacokinetics and Pharmacodynamics

6.1.2. Medical

6.1.3. Others

6.2. Global Radioisotopes Labeling Services Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. C-14

6.2.2. H-3

6.2.3. I-125

6.2.4. Others

6.3. Global Radioisotopes Labeling Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Radioisotopes Labeling Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Radioisotopes Labeling Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Radioisotopes Labeling Services Market Competition by Key Manufacturers

8.1. Global Radioisotopes Labeling Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Radioisotopes Labeling Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Charles River

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Eurofins Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. PerkinElmer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sekisui Medical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eckert & Ziegler

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Labcorp

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. XenoTech (BioIVT)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Quotient Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gifford Bioscience

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. ITM Radiopharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Almac Group

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Accelera

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Novandi Chemistry

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. AptoChem

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. HMR

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. AM Chemicals

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. PolyPeptide Group

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. NovoPro Bioscience

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Institute of Isotopes

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Nuvisan

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Revvity

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Necsa

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Fluorizon

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Edinburgh Pharmaceutical Processes

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Chelatec

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Pharmaron

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Medicilon

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. JOINN Laboratories

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. Frontage

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

9.30. Abace Biotechnology

9.30.1. Company Basic Information and Sales Area

9.30.2. Main Business/Business Overview

9.30.3. Product Portfolio

9.30.4. Financial

9.30.5. Recent Industry Insights

9.30.6. SWOT Analysis

9.31. Beijing Atom High-Tech

9.31.1. Company Basic Information and Sales Area

9.31.2. Main Business/Business Overview

9.31.3. Product Portfolio

9.31.4. Financial

9.31.5. Recent Industry Insights

9.31.6. SWOT Analysis

9.32. Wuxi Beita Pharmatech

9.32.1. Company Basic Information and Sales Area

9.32.2. Main Business/Business Overview

9.32.3. Product Portfolio

9.32.4. Financial

9.32.5. Recent Industry Insights

9.32.6. SWOT Analysis

9.33. Beijing North Institute of Biotechnology

9.33.1. Company Basic Information and Sales Area

9.33.2. Main Business/Business Overview

9.33.3. Product Portfolio

9.33.4. Financial

9.33.5. Recent Industry Insights

9.33.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Radioisotopes Labeling Services Market

Figure 4: Global Radioisotopes Labeling Services Market: Drivers

Figure 5: Global Radioisotopes Labeling Services Market: Challenges

Figure 6: Global Radioisotopes Labeling Services Market: Trends

Figure 7: Global Radioisotopes Labeling Services Market: Opportunity

Figure 8: Global Radioisotopes Labeling Services Market: Restraint

Figure 9: Global Radioisotopes Labeling Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Radioisotopes Labeling Services Market Value (USD Million) By Region

Figure 15: Global Radioisotopes Labeling Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Radioisotopes Labeling Services Market Value (USD Million) By Region

Figure 23: Global Radioisotopes Labeling Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Radioisotopes Labeling Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Radioisotopes Labeling Services Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Radioisotopes Labeling Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Radioisotopes Labeling Services Market Value (USD Million) By Region

Table 10: Global Radioisotopes Labeling Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Radioisotopes Labeling Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Radioisotopes Labeling Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Radioisotopes Labeling Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Charles River Basic Information And Sales Area

Table 31: Charles River. Products Portfolio

Table 32: Eurofins Scientific Basic Information And Sales Area

Table 33: Eurofins Scientific. Products Portfolio

Table 34: PerkinElmer Basic Information And Sales Area

Table 35: PerkinElmer. Products Portfolio

Table 36: Sekisui Medical Basic Information And Sales Area

Table 37: Sekisui Medical. Products Portfolio

Table 38: Eckert & Ziegler Basic Information And Sales Area

Table 39: Eckert & Ziegler. Products Portfolio

Table 40: Labcorp Basic Information And Sales Area

Table 41: Labcorp. Products Portfolio

Table 42: XenoTech (BioIVT) Basic Information And Sales Area

Table 43: XenoTech (BioIVT). Products Portfolio

Table 44: Quotient Sciences Basic Information And Sales Area

Table 45: Quotient Sciences. Products Portfolio

Table 46: Gifford Bioscience Basic Information And Sales Area

Table 47: Gifford Bioscience. Products Portfolio

Table 48: ITM Radiopharma Basic Information And Sales Area

Table 49: ITM Radiopharma. Products Portfolio

Table 50: Almac Group Basic Information And Sales Area

Table 51: Almac Group. Products Portfolio

Table 52: Accelera Basic Information And Sales Area

Table 53: Accelera. Products Portfolio

Table 54: Novandi Chemistry Basic Information And Sales Area

Table 55: Novandi Chemistry. Products Portfolio

Table 56: AptoChem Basic Information And Sales Area

Table 57: AptoChem. Products Portfolio

Table 58: HMR Basic Information And Sales Area

Table 59: HMR. Products Portfolio

Table 60: AM Chemicals Basic Information And Sales Area

Table 61: AM Chemicals. Products Portfolio

Table 62: PolyPeptide Group Basic Information And Sales Area

Table 63: PolyPeptide Group. Products Portfolio

Table 64: NovoPro Bioscience Basic Information And Sales Area

Table 65: NovoPro Bioscience. Products Portfolio

Table 66: Institute of Isotopes Basic Information And Sales Area

Table 67: Institute of Isotopes. Products Portfolio

Table 68: Nuvisan Basic Information And Sales Area

Table 69: Nuvisan. Products Portfolio

Table 70: Revvity Basic Information And Sales Area

Table 71: Revvity. Products Portfolio

Table 72: Necsa Basic Information And Sales Area

Table 73: Necsa. Products Portfolio

Table 74: Fluorizon Basic Information And Sales Area

Table 75: Fluorizon. Products Portfolio

Table 76: Edinburgh Pharmaceutical Processes Basic Information And Sales Area

Table 77: Edinburgh Pharmaceutical Processes. Products Portfolio

Table 78: Chelatec Basic Information And Sales Area

Table 79: Chelatec. Products Portfolio

Table 80: Pharmaron Basic Information And Sales Area

Table 81: Pharmaron. Products Portfolio

Table 82: Medicilon Basic Information And Sales Area

Table 83: Medicilon. Products Portfolio

Table 84: JOINN Laboratories Basic Information And Sales Area

Table 85: JOINN Laboratories. Products Portfolio

Table 86: Frontage Basic Information And Sales Area

Table 87: Frontage. Products Portfolio

Table 88: Abace Biotechnology Basic Information And Sales Area

Table 89: Abace Biotechnology. Products Portfolio

Table 90: Beijing Atom High-Tech Basic Information And Sales Area

Table 91: Beijing Atom High-Tech. Products Portfolio

Table 92: Wuxi Beita Pharmatech Basic Information And Sales Area

Table 93: Wuxi Beita Pharmatech. Products Portfolio

Table 94: Beijing North Institute of Biotechnology Basic Information And Sales Area

Table 95: Beijing North Institute of Biotechnology. Products Portfolio

Table 96: Global Market Value (USD Million) (2025-2032) By Application

Table 97: Global Market Share (%) By Application (2032)

Table 98: Global Market Value (USD Million) (2025-2032) By Types

Table 99: Global Market Share (%) By Types (2032)

Table 100: Global Radioisotopes Labeling Services Market Value (USD Million) By Region

Table 101: Global Radioisotopes Labeling Services Market Share (%) By Region (2025-2032)

Table 102: North America Market Value (USD Million) (2025-2032) By Country

Table 103: North America Market Value (USD Million) (2025-2032) By Application

Table 104: North America Market Value (USD Million) (2025-2032) By Types

Table 105: Europe Market Value (USD Million) (2025-2032) By Country

Table 106: Europe Market Value (USD Million) (2025-2032) By Application

Table 107: Europe Market Value (USD Million) (2025-2032) By Types

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 110: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 111: South America Market Value (USD Million) (2025-2032) By Country

Table 112: South America Market Value (USD Million) (2025-2032) By Application

Table 113: South America Market Value (USD Million) (2025-2032) By Types

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 116: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

FAQs

1. What is the current market size?

The Radioisotopes Labeling Services market size was valued at USD 1.2 billion in 2023, driven by demand in pharmaceutical and biomedical research sectors.

2. What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, reflecting expanding applications in diagnostics and drug development.

3. What are the key growth drivers?

Key drivers include rising R&D investments in pharmaceuticals, advancements in personalized medicine, and growing demand for radiolabeled compounds in cancer research.

4. What challenges hinder market growth?

Challenges include stringent regulatory compliance, high handling costs for radioactive materials, and limited skilled professionals in nuclear labeling techniques.

5. Who are the regional market leaders?

North America leads due to advanced healthcare infrastructure, followed by Europe. Asia-Pacific is emerging as a fast-growing region due to expanding biotech hubs.

6. Which companies dominate the market?

Leading players include CytImmune Sciences, Moravek, and Isogenica, focusing on innovative labeling solutions and strategic partnerships for global reach.

7. What future opportunities exist?

Opportunities lie in expanding oncology diagnostics, non-invasive imaging technologies, and increased adoption of radiolabeled biomarkers in clinical trials.

8. How does technology impact the market?

Automation, AI-driven analysis, and isotope synthesis advancements are improving labeling precision, reducing costs, and accelerating time-to-market for radiopharmaceuticals.

9. What is the regulatory environment?

Regulatory bodies like FDA and EMA enforce strict safety protocols, ensuring compliance with radiation handling standards while encouraging innovation through streamlined approvals.

10. How do partnerships shape market dynamics?

Strategic collaborations between labeling service providers and pharmaceutical firms are critical for co-developing targeted therapies and expanding market penetration.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Radioisotopes Labeling Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Charles River; Eurofins Scientific; PerkinElmer; Sekisui Medical; Eckert & Ziegler; Labcorp; XenoTech (BioIVT); Quotient Sciences; Gifford Bioscience; ITM Radiopharma; Almac Group; Accelera; Novandi Chemistry; AptoChem; HMR; AM Chemicals; PolyPeptide Group; NovoPro Bioscience; Institute of Isotopes; Nuvisan; Revvity; Necsa; Fluorizon; Edinburgh Pharmaceutical Processes; Chelatec; Pharmaron; Medicilon; JOINN Laboratories; Frontage; Abace Biotechnology; Beijing Atom High-Tech; Wuxi Beita Pharmatech; Beijing North Institute of Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options